Salacia reticulata for Health & Longevity

Created on 11/03/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Salacia reticulata is a climbing plant used to soften after-meal blood sugar spikes by slowing carbohydrate digestion. It modestly lowers fasting and long-term blood sugar in early or established type 2 diabetes; with normal blood sugar, the expected gain is smaller and less certain. Expected side effects are gas and bloating; blood sugar can fall too low with insulin or certain oral diabetes drugs. Evidence is small, short-term, often company-linked. (Full Review)

Protocol

Standardized extract
500 mg/day
As 250 mg root-bark extract twice daily for 6 weeks, or standardized extract for 12 weeks in prediabetes
Low-dose meal-split regimen
240 mg/day
60 mg before breakfast and lunch, 120 mg before dinner
Time of day
With carbohydrate-containing meals
Immediately before or with the meal; the effect is meal-bound
Time to effect
HbA1c
3 months
Long-term blood sugar marker
Fasting glucose
Weeks 3–6
Shift seen in prediabetes
Post-meal glucose blunting
Same meal
Requires starch or sugar in the meal

Benefits

Contraindications
  • Pregnancy (Avoid)
  • Breastfeeding
  • Inflammatory bowel disease, colonic ulceration, partial or predisposed intestinal obstruction, chronic malabsorption
  • Cirrhosis
  • Insulin or sulfonylurea users with recurrent or unrecognized hypoglycemia (level 2, below 54 mg/dL) without glucose monitoring
Key Interactions
  • Sulfonylureas (glibenclamide/glyburide, glimepiride): additive glucose lowering
Theoretical (inferred from mechanism)
  • Insulin and meglitinides (repaglinide, nateglinide): additive glucose lowering could cause hypoglycemia
  • Alpha-glucosidase inhibitor drugs (acarbose, miglitol): additive gas, bloating and diarrhea, plus further glucose lowering
  • GLP-1 receptor agonists (semaglutide, liraglutide) and DPP-4 inhibitors (sitagliptin): additive glucose lowering and gastrointestinal effects
  • CYP1A2 substrates (caffeine, theophylline, clozapine): raised levels could cause caffeine jitteriness or theophylline or clozapine toxicity
  • Over-the-counter digestive enzymes (amylase, pancreatin) and activated charcoal: may reduce Salacia's effect
  • Glucose-lowering supplements (berberine, cinnamon, mulberry leaf): additive glucose lowering
  • Glucose-raising drugs (thiazide diuretics such as hydrochlorothiazide; corticosteroids such as prednisone): may offset Salacia's effect
  • Elective surgery: additive glucose lowering during fasting and anesthesia

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gas, bloating and abdominal discomfort; hypoglycemia with glucose-lowering drugs
  • Speculative: Pregnancy loss and low birth weight; chromosomal damage signal; liver enlargement and altered drug metabolism

Monitoring

Marker Target Why
HbA1c 4.0–5.6% (standard reference range) Primary trial outcome
Fasting plasma glucose 70–99 mg/dL (standard reference range) Expected to change
Post-meal glucose (continuous glucose monitor) No established target; track peak rise and 2-hour return versus own baseline meals Direct readout of the mechanism
LDL cholesterol <100 mg/dL (standard reference range) Expected to change
Triglycerides <150 mg/dL (standard reference range) Expected to change
Glucose during low-sugar symptoms At or above 70 mg/dL Safety check for sulfonylurea or insulin users

Cadence: Baseline HbA1c, fasting glucose and lipid panel; post-meal glucose checks during the first 1–2 weeks, fasting glucose and lipids at 6 weeks, HbA1c at 3 months, then every 6–12 months

Qualitative Assessment

  • Gas, bloating or loose stools after dosed meals (tolerance)
  • Post-meal energy and drowsiness
  • Hunger and fullness between meals
  • Shakiness, sweating or confusion suggesting hypoglycemia (for glucose-lowering drug users)